William Fodor - Biostage Chief Officer
| BSTGDelisted Stock | USD 4.20 0.09 2.10% |
Insider
William Fodor is Chief Officer of Biostage
| Age | 64 |
| Phone | 774 233 7300 |
| Web | https://biostage.com |
Biostage Management Efficiency
The company has return on total asset (ROA) of (2.1066) % which means that it has lost $2.1066 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.9228) %, meaning that it created substantial loss on money invested by shareholders. Biostage's management efficiency ratios could be used to measure how well Biostage manages its routine affairs as well as how well it operates its assets and liabilities.Biostage currently holds 115 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Biostage has a current ratio of 2.21, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Biostage until it has trouble settling it off, either with new capital or with free cash flow. So, Biostage's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biostage sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biostage to invest in growth at high rates of return. When we think about Biostage's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Elaine Zhang | Covalon Technologies | N/A | |
| MBA DO | Antibe Therapeutics | 57 | |
| Kieran FCA | Sosei Group | N/A | |
| Jay Carlson | Mosaic Immunoengineering | N/A | |
| Steven King | Mosaic Immunoengineering | 59 | |
| Andrew Liu | SanBio Company Limited | N/A | |
| Nicole Steinmetz | Mosaic Immunoengineering | 43 | |
| Greg Leszczynski | Covalon Technologies | N/A | |
| Dr MBA | Cellectis SA | 46 | |
| MSc MSc | Cellectis SA | 54 | |
| Joseph MPH | Mosaic Immunoengineering | 50 | |
| LLB JD | Antibe Therapeutics | 65 | |
| Naoki Tsukahara | SanBio Company Limited | N/A | |
| Pascalyne Wilson | Cellectis SA | N/A | |
| Candelle Chong | Sosei Group | N/A | |
| Cyril Empig | Mosaic Immunoengineering | N/A | |
| Greg Gillas | SanBio Company Limited | N/A | |
| Valerie Cros | Cellectis SA | N/A | |
| Hironoshin Nomura | Sosei Group | N/A | |
| Kazumi Sawaguchi | SanBio Company Limited | N/A | |
| Miles Congreve | Sosei Group | N/A | |
Management Performance
| Return On Equity | -4.92 | |||
| Return On Asset | -2.11 |
Biostage Leadership Team
Elected by the shareholders, the Biostage's board of directors comprises two types of representatives: Biostage inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biostage. The board's role is to monitor Biostage's management team and ensure that shareholders' interests are well served. Biostage's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biostage's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yu Hong, President | ||
| Joseph Damasio, Chief Officer | ||
| David Green, CEO Chairman | ||
| Shunfu Hu, VP Operations | ||
| William Fodor, Chief Officer |
Biostage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Biostage a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.92 | |||
| Return On Asset | -2.11 | |||
| Current Valuation | 78.64 M | |||
| Shares Outstanding | 11.64 M | |||
| Shares Owned By Insiders | 50.95 % | |||
| Number Of Shares Shorted | 121.66 K | |||
| Price To Earning | (0.16) X | |||
| Price To Book | 28.47 X | |||
| EBITDA | (8.36 M) | |||
| Net Income | (7.98 M) |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Biostage OTC Stock
If you are still planning to invest in Biostage check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biostage's history and understand the potential risks before investing.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |